News

Arbutus and Vaccitech Dose First Patient in Phase 2a Clinical Trial Combining Therapies for the Treatment of Chronic Hepatitis B Virus

Trial will evaluate AB-729, an RNAi therapy in combination with VTP-300, an immunotherapeutic, and NA therapyWARMINSTER, Pa. and OXFORD, United…

2 years ago

Century Therapeutics to Host Virtual Research and Development Day on June 13, 2022

PHILADELPHIA, June 06, 2022 (GLOBE NEWSWIRE) -- Century Therapeutics (NASDAQ: IPSC), an innovative biotechnology company developing induced pluripotent stem cell…

2 years ago

Jushi Holdings Inc. Opens 33rd Retail Location Nationwide and Fourth Dispensary in Nevada

NuLeaf Las Vegas The Strip, Located by 18b Las Vegas Arts District on The Las Vegas Strip, to Begin Serving…

2 years ago

BridgeBio Pharma to Participate in June Investor Events

PALO ALTO, Calif., June 06, 2022 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a commercial-stage…

2 years ago

Titan Medical Appoints Bill Fahey as Vice President, Manufacturing and Operations

TORONTO, June 06, 2022 (GLOBE NEWSWIRE) -- Titan Medical Inc. (Nasdaq: TMDI; TSX: TMD), a medical device company focused on the…

2 years ago

VitalHub Signs Multi-Year Licensing Agreement to Provide an Electronic Medical Record Solution for Provincial Adult Correctional Facilities across Ontario

TORONTO, June 06, 2022 (GLOBE NEWSWIRE) -- VitalHub Corp. (the “Company”) (TSX: VHI) is pleased to announce that TREAT has…

2 years ago

Radius Files Definitive Proxy and Mails Letter to Stockholders

Urges Stockholders to Vote “FOR” Radius’ Highly Qualified, Independent Director Nominees – Catherine J. Friedman, Jean-Pierre Garnier, Ph.D. and Andrew…

2 years ago

Quipt Home Medical on Preliminary List to Join Russell Microcap® Index

CINCINNATI, June 06, 2022 (GLOBE NEWSWIRE) -- Quipt Home Medical Corp. (“Quipt” or the “Company”) (NASDAQ:QIPT; TSXV:QIPT), a U.S. based…

2 years ago

Biogen and Alectos Therapeutics Announce License and Collaboration Agreement for AL01811, a Novel GBA2 Inhibitor for the Potential Treatment of Parkinson’s Disease

Cambridge, Mass. and Burnaby, British Columbia , June 06, 2022 (GLOBE NEWSWIRE) -- Biogen and Alectos Therapeutics Announce License and…

2 years ago

Arcutis Announces Positive Topline Results from STRATUM Pivotal Phase 3 Trial of Roflumilast Foam 0.3% in Seborrheic Dermatitis

Study met its primary endpoint with 80.1% of individuals treated with roflumilast foam achieving Investigator Global Assessment (IGA) Success compared…

2 years ago